Switzerland-based Roche (SIX: RO, ROG;OTCQX: RHHBY) has received Emergency Use Authorisation from the United States Food and Drug Administration (FDA) for its Elecsys Anti-SARS-CoV-2 S antibody test, it was reported on Tuesday.
The test can be utilised to measure the level of antibodies in people that have been exposed to the SARS-CoV-2 virus. It is aimed at antibodies that are directed against the region of the novel coronavirus known as the spike protein, specifically the area that allows the virus cell to bind to the host cell receptor, that is required for the virus to enter the host cell. It also offers a numerical result from 0.40-250 U/mL and a qualitative result. It runs on the company's widely available cobas e analysers.
The company is to start shipping the Elecsys Anti-SARS-CoV-2 S test to United States laboratories in the next week. The first lab to provide the testing option in the United States is LabCorp, an early adopter of the test with broad geographic reach.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial